EU Critical Medicines Act: What the New Rules Mean for Drug Shortages in Europe

The EU Critical Medicines Act will change how European hospitals and health ministries buy medicines by making security of supply a mandatory award criterion, not an optional extra. The Council and the European Parliament reached a provisional political agreement on 12 May 2026, and the text is now in legal-linguistic revision ahead of formal adoption, with publication in the Official Journal expected towards the end of 2026. For EU patients, the practical effect will arrive gradually: the Act reshapes procurement and manufacturing incentives for a defined list of critical medicines, but it does not switch off shortages at the pharmacy counter in 2026 or 2027.

That distinction matters, and it is the part of the debate that gets least attention. The Act is an industrial policy instrument dressed as a health law. It attacks the structural causes of medicine shortages Europe has lived with for a decade, while the daily experience of a pharmacist in Kraków, Naples or Rotterdam is governed by something the Act barely touches: national pricing.

What the EU Critical Medicines Act actually does

The Critical Medicines Act is an EU regulation that obliges contracting authorities across member states to apply resilience-related requirements when procuring critical medicines, enables collaborative cross-border procurement, and creates support for strategic manufacturing projects for critical medicines and their active pharmaceutical ingredients inside the EU.

Three mechanisms sit at its core. First, procurement reform: price can no longer be the sole award criterion for medicines on the Union list. Contracting authorities must weigh security of supply, supply chain resilience and EU manufacturing capacity. Second, strategic projects: a pathway for prioritised support to manufacturing investments in critical medicines and their ingredients on European soil. Third, collaborative procurement, where the co-legislators made one of the most consequential and least reported changes in the whole file.

In the provisional agreement, the number of member states required to request that the Commission procure on their behalf was cut from nine to five. Nine states is a coalition that takes a political crisis to assemble. Five is achievable by a regional bloc with a common clinical problem, for example a group of smaller member states facing the same paediatric antibiotic gap. That single numerical change is what turns joint procurement from a theoretical instrument into a usable one.

Lawmakers also extended the scope to orphan medicines, meaning treatments for rare diseases became eligible for strategic projects and collaborative procurement mechanisms. That was a late win for the rare disease community and it broadens the Act well beyond the antibiotics-and-painkillers framing used in most coverage.

Why medicine shortages keep happening in Europe

Shortages persist because Europe consumes medicines it has largely stopped making. The European Commission estimates that around 80% of active pharmaceutical ingredients used in EU generic medicines are manufactured outside Europe, principally in China and India. When a single plant in Asia halts production, the shortage propagates simultaneously into every member state.

Commission analysis has found that over 50% of recent critical medicine shortages in the EU were caused by manufacturing issues, compounded by that concentrated dependence on non-EU API supply. This is not primarily a demand problem or a stockpiling problem. It is a manufacturing fragility problem with a single point of failure sitting thousands of kilometres outside EU jurisdiction.

The economics explain the concentration. Off-patent antibiotics, anaesthetics and older cardiovascular drugs are sold at prices set through tenders that historically rewarded the lowest bidder. Margins on some generic injectables are measured in cents per unit. Under those conditions, no rational manufacturer builds a European plant. Production consolidated where costs are lowest, and resilience was the casualty.

Which medicines are on the critical list

The Union list of critical medicines, maintained by the European Medicines Agency, contains over 270 active substances following its December 2024 update, covering treatments for infections, cardiovascular disease and mental health conditions. Its first annual review began tracking updates in March 2026, adding and adjusting substances and recognising new ATC codes as critical.

Inclusion on the list is not a prediction of shortage. It signals that a disruption would cause significant patient harm, so prevention is prioritised. Under the Act, supply chain vulnerability assessments for over 200 active substances become a legislative obligation rather than a voluntary exercise, work coordinated through the EMA's Executive Steering Group on Shortages and Safety of Medicinal Products.

The list skews heavily towards older, cheap, off-patent products. That is precisely the segment where European manufacturing has thinned out, which is why the Act's authors targeted it.

What the latest data says about patients and pharmacists

The most important recent evidence is not from Brussels but from the counter. The PGEU Medicine Shortages Report 2025, based on a survey of 27 EU and EFTA countries conducted between 15 January and 15 February 2026, found that 96% of responding countries report persistent shortages, with over 600 medicines in shortage in more than one third of countries.

Two findings deserve more attention than they received. Community pharmacies now spend an average of 12 hours per week managing shortages, double the level of five years ago. And for the first time, reduced patient trust emerged as the most frequently reported consequence of shortages, ahead of clinical consequences. Nearly 9 in 10 member states report treatment interruptions, and 81% report increased administrative duties and financial losses in pharmacies.

Mikołaj Konstanty, PGEU President, put it directly: "Medicine shortages have stabilized, but at an unacceptably high level. They are no longer isolated incidents; they are a chronic strain on patients, pharmacists and healthcare systems."

That trust finding is the underreported story. The Critical Medicines Act is engineered to fix supply chains over five to ten years. The measurable damage in 2026 is institutional confidence, accumulating now, and no procurement regulation repairs it directly.

Who carries the cost

The burden falls unevenly. Patients on long-term medication for epilepsy, diabetes, hypertension or psychiatric conditions face the sharpest risk, because substitution is clinically delicate and interruption is dangerous. Only 15% of surveyed countries permit therapeutic substitution by pharmacists, meaning in most member states a pharmacist who has found an equivalent product must still send the patient back to a doctor for a new prescription.

That extra step is a fee, a day off work and a journey. For low-income households, elderly patients in rural Poland, Spain or Greece, and people without flexible employment, the practical result is a missed dose cycle. Paediatric formulations are a second pressure point: parents in Germany, France and Italy have repeatedly faced antibiotic suspension shortages during winter respiratory seasons, with pharmacists compounding substitutes by hand.

What critics and generic manufacturers say

Industry support is real but conditional. Adrian van den Hoven, Director General of Medicines for Europe, welcomed the Parliament's position and applauded "the progressive position to advance Europe's health security", while stating the sector is ready to work with co-legislators on an act enabling the off-patent industry "to be competitive, especially in today's unpredictable geopolitical landscape".

The caveat is pricing. Medicines for Europe has warned that obligations imposed outside the health framework, including Extended Producer Responsibility mechanisms under the Urban Wastewater Treatment Directive, "undermine supply-chain planning, disproportionately impacting low-margin generic medicines". The argument is straightforward: procurement criteria that reward resilience mean little if the underlying reimbursement price still makes European antibiotic production loss-making.

There is a structural tension the Act does not resolve. Medicine pricing and reimbursement remain national competences. Finance ministries under budget pressure in every member state retain strong incentives to award on price. The Act tells them they must consider resilience; it cannot force them to pay for it.

External critics have raised a further point: prioritising EU-based manufacturing for critical medicines could redirect global supply and affect availability in lower-income regions, a concern voiced during the Parliament's consideration of the file.

How joint procurement, stockpiling and EMA monitoring will work

Under the agreed framework, five or more member states can request that the Commission run a procurement on their behalf, pooling volume to attract suppliers into markets too small to serve individually. This echoes the vaccine model used during the pandemic, applied to routine off-patent products.

Emer Cooke, EMA Executive Director, described the provisional agreement as "an important step in strengthening the resilience, security and sustainability" of the EU medicine supply and a significant milestone for Europe's production capacity.

Operationally, the EMA's role hardens around the European Shortages Monitoring Platform (ESMP), the digital system through which industry and national regulators exchange shortage data. The agency is expanding its functionality so notifications flow faster and more consistently across all 27 member states, replacing the fragmented national reporting that made early warning unreliable. Readers following our health articles will recognise this as the same interoperability challenge running through EU health data policy generally.

What EU patients should do now

Concrete steps for patients and pharmacy staff across member states:

Order repeat prescriptions 7 to 10 days early if you take long-term medication for epilepsy, diabetes, cardiovascular or psychiatric conditions. This gives your pharmacist time to source alternatives without an interruption.
Ask your pharmacist to check the national shortage register before your supply runs out. Most member states operate a reporting system accessible to pharmacists.
Request a substitution-friendly prescription from your doctor where clinically appropriate, given that only 15% of countries let pharmacists substitute independently.
Never split or ration doses to stretch a supply. Contact your prescriber for a clinically supervised alternative instead.
Report persistent shortages to your national medicines agency. Under-reporting weakens the ESMP data that will drive Union list reviews.
Pharmacy owners should document time and cost spent on shortage management, as national remuneration debates increasingly rely on this evidence.

For continuing coverage of EU health and consumer policy, see Baba International.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

When does the EU Critical Medicines Act come into force?

Political agreement was reached on 12 May 2026. The text requires formal endorsement by the Council and Parliament following legal-linguistic revision, with Official Journal publication expected towards the end of 2026. The date of application will be confirmed at publication, and key obligations will phase in afterwards.

Will the Act stop medicine shortages immediately?

No. The Act addresses structural causes: supply chain concentration, procurement incentives and EU manufacturing capacity. Building or requalifying manufacturing lines takes years. Expect measurable improvement over the medium term rather than in the next winter season.

Which medicines does it cover?

The Union list of critical medicines, containing over 270 active substances as of the December 2024 update and revised annually from March 2026. Coverage was extended in the provisional agreement to include orphan medicines for rare diseases.

Does the Act change what I pay for medicines?

Not directly. Pricing and reimbursement remain national competences of each member state. The Act changes how contracting authorities award supply contracts, which could raise procurement costs modestly where resilience criteria favour EU-based production.